Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05165446 · ClinicalTrials.gov registry record
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
A clinical trial of NASH - Nonalcoholic Steatohepatitis, sponsored by Natalie Torok.
- Active
- Registry status
- 35
- Enrollment target
- 1
- Study location
NCT05165446: Active study of NASH - Nonalcoholic Steatohepatitis, sponsored by Natalie Torok.
NCT05165446 is a study of NASH - Nonalcoholic Steatohepatitis that is active but no longer recruiting, run by Natalie Torok. The registered enrollment target is 35 participants, below the 261-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05165446, a study of NASH - Nonalcoholic Steatohepatitis, is active but no longer recruiting, sponsored by Natalie Torok.
- ACTIVE NOT RECRUITING
- Registry status
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this proposal is to investigate a novel imaging method to identify patients with non-alcoholic steatohepatitis (NASH) who are at risk for hepatocellular carcinoma (HCC).
Primary Outcome
Safety:MRE evaluation of the liver for stiffness is a standard of care test. We do not expect issues as this is a non-invasive technique. Our MR may require a longer session compared to the traditional MRE (40 minutes of scan time for multifrequency MRE, as compared to 25 minutes for conventional MRE). However, all issues, patient symptoms will be recorded. Technical Feasibility: The MRE algorithm we will use has previously been shown to produce data from a different scanner platform, across al
Conditions Studied
Study Locations (1)
California
- Stanford Hospital - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2025-09-30 |
What the registry record for NCT05165446 still lists
NCT05165446 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 261-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 0 interventions.
NCT05165446 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05165446 about?
NCT05165446 is a clinical study titled "Novel MRE Technique to Assess a Risk Factor for Liver Cancer". The aim of this proposal is to investigate a novel imaging method to identify patients with non-alcoholic steatohepatitis (NASH) who are at risk for hepatocellular carcinoma (HCC).
What is the current status of trial NCT05165446?
This trial is currently active not recruiting. The enrollment target is 35 participants. The study started on 2022-01-27. Estimated completion is 2025-09-30.
What conditions does trial NCT05165446 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
Who is sponsoring clinical trial NCT05165446?
This trial is sponsored by Natalie Torok, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05165446 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05165446's enrollment target sits among peer trials
35 24th of 28 higher than 5 of 28 other NASH - Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NASH - Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RECRUITING · Phase 3
-
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI